Trans Atlantic acquisition for medicines producer

Rosemont Pharmaceuticals, a Leeds-based leading developer, manufacturer, and distributor of liquid medicines, has acquired Sabal Therapeutics and its affiliates.

The deal, which includes affiliates Metacel Pharmaceuticals, Palmetto Pharmaceuticals, Athena Bioscience and Sarras Health, is for a group of privately owned specialty pharmaceutical companies and distributors of prescription, liquid medicines, based in Georgia, USA.

This acquisition is intended to further enhance Rosemont’s ability to serve patients with swallowing difficulties across the USA.

Previously, the business has developed, registered and supplied medicines to the US market via distribution partners.

This acquisition now provides it with the ability to supply branded and generic medicines directly into the US market.

In addition to the existing portfolio included in this transaction, Rosemont has an extensive pipeline of novel, liquid medicines designed for the US market and patients.

Howard Taylor, CEO of Rosemont, said: “Acquiring Sabal is a key milestone for us to commercialise our world class medicines to help US patients with swallowing difficulties, building on our platform of high-quality development teams in both the UK and Greece.

“Our vice president for the US Market, John Denman, who heads our Rosemont Inc US operations, will be leading this venture and all of us at Rosemont are looking forward to working with the Sabal team.”

Sabal president and CEO, Jeff Bryant, added: “this fusion of Rosemont and Sabal allows us to greatly expand our vision across therapeutic areas, with the ultimate mission of changing patients’ lives for the better.

“We are happy to join the Rosemont team to deliver even greater value to our providers and those in their care.”